Explore the challenges and advancements in managing FCS with expert insights on treatment and patient care.
Back
RX Review: Leveraging siRNA in FCS Management
Christie Ballantyne, MD, and Viet Le, DMSc, PA-C, discuss the changing landscape of familial chylomicronemia syndrome management and how the introduction of plozasiran impacts care.
RX Review: Leveraging siRNA in FCS Management
Episodes
All
All
Discover effective strategies to shorten the diagnostic window for pancreatitis and manage high triglyceride levels in FCS.
Understanding severe hypertriglyceridemia is crucial for preventing pancreatitis and managing triglyceride levels effectively.
Panelists break down the potential role of plozasiran in FCS based on the PALISADE trial.
Explore how the latest FDA approvals impact the management of FCS.
Explore the critical role of nutrition and pharmacologic therapies in managing hypertriglyceridemia and preventing pancreatitis effectively.
Advertisement
Advertisement
Trending on HCPLive
1
Furoscix ReadyFlow (Furosemide) and its Impact on HF, CKD Edema Treatment
2
Odevixibat Fails to Improve Native Liver Survival in Phase 3 BOLD Trial for Biliary Atresia
3
Survey Reveals Low Awareness of Chronic Hepatitis B’s Link to Liver Cancer
4
Omalizumab Outperforms Multiallergen OIT for Multifood Allergy
5